The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration
Open accessAbstract
Neurotrophic factors play key roles in the development and survival of neurons. The potent neuroprotective effects of neurotrophic factors, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell-line derived neurotrophic factor (GDNF) and nerve growth factor (NGF), suggest that they are good therapeutic candidates for neurodegenerative diseases. Glaucoma is a neurodegenerative disease of the eye that causes irreversible blindness. It is characterized by damage to the optic nerve, usually due to high intraocular pressure (IOP), and progressive degeneration of retinal neurons called retinal ganglion cells (RGCs). Current therapy for glaucoma focuses on reduction of IOP, but neuroprotection may also be beneficial. BDNF is a powerful neuroprotective agent especially for RGCs. Exogenous application of BDNF to the retina and increased BDNF expression in retinal neurons using viral vector systems are both effective in protecting RGCs from damage. Furthermore, induction of BDNF expression by agents such as valproic acid has also been beneficial in promoting RGC survival. In this review, we discuss the therapeutic potential of neurotrophic factors in retinal diseases and focus on the differential roles of glial and neuronal TrkB in neuroprotection. We also discuss the role of neurotrophic factors in neuroregeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Purification of a new neurotrophic factor from mammalian brain.
Barde, Y. A., Edgar, D., & Thoenen, H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01207.x · Cited by 1,822 · cited 1×
“BDNF was originally purified from the pig brain as a factor that promotes survival and neurite outgrowth of cultured embryonic chick sensory neurons [17].”
BackgroundPhiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 1×
“Its antiepileptic features have been attributed to the stimulation of the brain γ-aminobutyric acid (GABA) transmission, and more recently, it was discovered that VPA is a class of histone deacetylase (HDAC) inhibitors [129,130].”
BackgroundNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Sortilin is essential for proNGF-induced neuronal cell death
Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T. E., et al. (2004) · Nature · doi:10.1038/nature02319 · Cited by 962 · cited 1×
“Stimulation of these receptors in neurons can produce opposing effects, in which TrkA activation is associated with neuronal survival, whereas p75NTR activation is implicated in neuronal apoptosis [7–10].”
BackgroundGDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820 · cited 1×
“The potency of neurotrophic factors, particularly NGF, BDNF, CNTF and GDNF, in promoting neuronal survival has raised much hope for their therapeutic use in neurodegenerative diseases including Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and glaucoma [2–4].”
BackgroundSustained axon regeneration induced by co-deletion of PTEN and SOCS3
Sun, F., Park, K. K., Belin, S., Wang, D., Lu, T., Chen, G., Zhang, K., Yeung, C., Feng, G., Yankner, B. A., et al. (2011) · Nature · doi:10.1038/nature10594 · Cited by 754 · cited 1×
“SOCS3 deletion in RGCs leads to robust axonal regeneration following optic nerve injury [63,64].”
BackgroundBernardos, R. L., Barthel, L. K., Meyers, J. R., & Raymond, P. A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1624-07.2007 · Cited by 647
Harada, T., Harada, C., Kohsaka, S., Wada, E., Yoshida, K., Ohno, S., Mamada, H., Tanaka, K., Parada, L. F., & Wada, K. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09228.2002 · Cited by 397
Self-citationEffect of CNTF on retinal ganglion cell survival in experimental glaucoma
Pease, M. E., Zack, D. J., Berlinicke, C., Bloom, K., Cone, F., Wang, Y., Klein, R. L., Hauswirth, W. W., & Quigley, H. A. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3013 · Cited by 222
Insights into the biological functions of Dock family guanine nucleotide exchange factors
Laurin, M., & Côté, J.-F. (2014) · Genes & Development · doi:10.1101/gad.236349.113 · Cited by 160
Birch, D. G., Bennett, L. D., Duncan, J. L., Weleber, R. G., & Pennesi, M. E. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.07.013 · Cited by 112
Rhee, K. D., Nusinowitz, S., Chao, K., Yu, F., Bok, D., & Yang, X.-J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303604110 · Cited by 92 · cited 1×
“It is highly potent against photoreceptor loss in several animal models of retinal disease, including retinitis pigmentosa [44–48] and against RGC death in models of glaucoma and ischaemic optic neuropathy [49–53].”
BackgroundMOCA Induces Membrane Spreading by Activating Rac1
Namekata, K., Enokido, Y., Iwasawa, K., & Kimura, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311275200 · Cited by 84 · cited 2×
“Dedicator of cytokinesis 3 (Dock3) is one of the atypical guanine exchange factors (GEFs) that regulate the activation of the Rho GTPase Rac1 [92].”
BackgroundSelf-citation
Cited by
Neuroprotective strategies for retinal disease
Pardue, M. T., & Allen, R. S. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.02.002 · Cited by 237
“Activation of BDNF-TrkB signaling through genetic means in animal models or through gene therapy demonstrate RGC survival (Kimura et al., 2016).”
Osborne, A., Khatib, T. Z., Songra, L., Barber, A. C., Hall, K., Kong, G. Y. X., Widdowson, P. S., & Martin, K. R. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1041-8 · Cited by 175
Tejeda, G., & Díaz-Guerra, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020268 · Cited by 126
“Therefore, besides treatments directed to decrease intraocular pressure, neurotrophic factors are currently considered as having great potential in glaucoma therapy (recently reviewed by [174]).”
BackgroundThe concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40
“There have been several attempts to utilize the neurotrophic factors, mainly brain-derived neurotrophic factor (BDNF), which plays a key role in the survival, plasticity, and growth of neurons, including RGCs (Dekeyster et al., 2015; Kimura et al., 2016; Kuo and Liu, 2022).”
BackgroundFocused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
Metadata
- Authors
- Kimura, A., Namekata, K., Guo, X., Harada, C., & Harada, T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-09-20
- Volume
- 17
- Issue
- 9
- Pages
- 1584
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2522303657
- Cited by
- 211
- References
- 15
- FWCI
- 12.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.